Women's Hormone Health: HRT, Perimenopause, and the Evidence Base

## The Hormone Health Landscape for Women Female hormone health is one of the fastest-moving areas in preventive medicine. For two decades following the 2002 Women's Health Initiative (WHI) study, hormone replacement therapy (HRT) was widely discouraged due to reported increases in breast cancer and cardiovascular risk. That interpretation has been substantially revised by subsequent analysis — the WHI's findings were specific to older, orally administered, synthetic hormones in women a decade past menopause. The current clinical picture is more nuanced and, for many women, more encouraging. ## The Hormonal Transition: Perimenopause and Menopause The **perimenopause** begins, on average, in a woman's mid-40s — sometimes earlier — and is characterised by erratic fluctuations in oestrogen and progesterone before levels settle at the lower post-menopausal baseline. This phase typically lasts 4–10 years and carries significant symptom burden for many women. The **menopausal transition** is defined retrospectively as 12 months of amenorrhoea without another cause. The average age of natural menopause in Western populations is 51–52. Declining oestrogen affects virtually every tissue in the body. Symptoms include: - Vasomotor symptoms — hot flushes and night sweats (affecting 60–80% of perimenopausal women) - Sleep disruption, often secondary to night sweats - Genitourinary syndrome of menopause (GSM) — vaginal dryness, urinary urgency, dyspareunia - Mood changes, anxiety, and cognitive effects (brain fog, memory lapses) - Accelerated bone loss — oestrogen is the primary regulator of bone remodelling in women - Metabolic shifts — increased visceral adiposity, altered lipid profiles, rising cardiovascular risk ## The Evidence for HRT: Reassessment of WHI The original 2002 WHI trial enrolled women aged 50–79 (mean age 63) and used oral conjugated equine oestrogen (CEE) plus medroxyprogesterone acetate (MPA), a synthetic progestogen. It reported a modest increase in breast cancer risk and early signals of cardiovascular harm. Subsequent analysis fundamentally changed the interpretation: **Timing hypothesis** — The cardiovascular risk in WHI was concentrated in older women who were more than 10 years post-menopause. Women who started HRT within 10 years of menopause showed **reduced** cardiovascular risk. A 2004 Danish randomised trial (Schierbeck et al.) confirmed this: women randomised to HRT within 10 years of menopause had a 52% lower rate of myocardial infarction, heart failure, and cardiovascular death (HR 0.48, 95% CI 0.26–0.87) compared to placebo over 10 years. **Route of administration** — Oral oestrogen undergoes first-pass hepatic metabolism, raising triglycerides and clotting factor production. Transdermal oestrogen bypasses this, producing more favourable effects on coagulation and cardiovascular risk markers. A 2015 British Million Women Study analysis found no increased risk of venous thromboembolism with transdermal versus oral oestrogen. **Progestogen type** — Synthetic MPA used in WHI differs pharmacologically from micronised progesterone (bioidentical). Micronised progesterone does not appear to carry the same breast cancer signal as MPA. The French E3N cohort study (Fournier et al., 2008) found no increased breast cancer risk in women using oestrogen combined with progesterone over 8 years, compared with a significant increase with MPA combinations. The **NICE Menopause Guideline (2015, updated 2023)** and the **British Menopause Society** now recommend HRT as first-line therapy for vasomotor symptoms in women under 60 or within 10 years of menopause where there are no contraindications. ## Testosterone in Women Female testosterone, produced by the ovaries and adrenal glands, is often overlooked. It declines with age and drops sharply after bilateral oophorectomy. Low testosterone in women is associated with reduced libido, fatigue, low mood, and impaired muscle maintenance. A 2019 systematic review and meta-analysis in *The Lancet Diabetes & Endocrinology* (Davis et al.) — the most comprehensive to date — reviewed 36 randomised trials and found that testosterone therapy in women: - Significantly improved sexual function across multiple domains (desire, arousal, orgasm, satisfaction) - Improved lean mass and muscle strength - Did not significantly affect cardiometabolic markers, cognitive function, or mood at physiological doses Australia's Therapeutic Goods Administration (TGA) approved a testosterone gel for women (Androfeme 1%) in 2006. The UK's MHRA approved Androfeme in 2024. In the US, no product is formally approved, but testosterone is widely prescribed off-label for postmenopausal women. ## Bioidentical Hormones "Bioidentical" refers to hormones chemically identical to those produced by the human body — 17β-oestradiol, progesterone, and testosterone. These differ from older synthetic hormones (CEE, MPA) in their molecular structure and receptor-binding behaviour. Several bioidentical products are FDA and TGA approved (Estrace, Prometrium, Androfeme). The term is sometimes misused by compounding pharmacies to imply custom-compounded preparations are inherently safer or more effective — this has not been demonstrated in clinical trials. Regulated bioidentical products have an established safety profile; custom compounded preparations are largely unstudied. ## What Women's Health Clinics Offer Women's health clinics in the BiohackMaps directory vary significantly. Services typically include: - **Hormone testing** — comprehensive panels including oestradiol, progesterone, testosterone, SHBG, DHEAS, thyroid function, and cortisol - **HRT prescription and management** — systemic oestrogen (patch, gel, spray), micronised progesterone, local oestrogen for GSM - **Testosterone therapy** — for libido, energy, and body composition - **Thyroid and adrenal support** — many perimenopausal symptoms overlap with thyroid dysfunction; good clinics assess both - **Nutrition and lifestyle integration** — bone density optimisation, metabolic support, sleep protocols - **Telehealth follow-up** — many clinics now offer hybrid models for prescription management and results review ## Choosing a Clinic The quality of women's hormone care varies enormously between providers. When evaluating a clinic: 1. **Confirm the prescribing clinician is a licensed physician** — ideally a gynaecologist, endocrinologist, or GP with specific menopause training (MSCP accreditation in the UK, NAMS certification in the US) 2. **Expect blood work before any prescription** — symptom-based prescribing without labs is not acceptable practice 3. **Ask about follow-up monitoring** — hormone levels, bone density, and mammographic surveillance should be part of ongoing care 4. **Be wary of clinics that default to compounded preparations** without a clinical rationale for why a regulated product is unsuitable 5. **Ask about the full cost structure** — labs, initial consultation, ongoing prescription management, and any required supplements